Narayan Pradeep
Department of Cardiac Surgery; Rabindranath Tagore International Institute of Cardiac Sciences, Narayana Health, 124, EM Bypass, Mukundapur, Kolkata, 700099 India.
Indian J Thorac Cardiovasc Surg. 2022 May;38(3):336-338. doi: 10.1007/s12055-022-01346-x. Epub 2022 Apr 5.
FAME III, a multi-centric randomized controlled trial compared fractional flow reserve (FFR) guided percutaneous coronary interventions (PCI) with coronary artery bypass grafting. The study confirmed that compared with FFR-guided-PCI, coronary artery bypass grafting was associated with a significantly lower incidence of the composite of mortality, stroke, MI, and repeat revascularizations at 1 year. Thus, FFR-guided-PCI failed to meet the "noninferiority" criteria.
FAME III是一项多中心随机对照试验,比较了血流储备分数(FFR)指导下的经皮冠状动脉介入治疗(PCI)与冠状动脉旁路移植术。该研究证实,与FFR指导下的PCI相比,冠状动脉旁路移植术在1年时与死亡率、中风、心肌梗死和再次血运重建的综合发生率显著降低相关。因此,FFR指导下的PCI未能达到“非劣效性”标准。